甲状腺微小乳头状癌的处理。
Management of Papillary Thyroid Microcarcinoma.
机构信息
Division of Diabetes, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; Knowledge and Evaluation Research Unit, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Division of Diabetes, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
出版信息
Endocrinol Metab Clin North Am. 2019 Mar;48(1):199-213. doi: 10.1016/j.ecl.2018.10.006. Epub 2018 Dec 23.
The worldwide incidence of thyroid cancer is increasing. A third of new thyroid cancer cases are papillary thyroid microcarcinoma (PTM), which are 1 cm or less. These tumors are mostly indolent with excellent prognosis. Although thyroid surgery is the most common management option for patients with PTM, new management options demand that treatment decisions must be individualized and based on patient's preference, context, and biology. This article describes management options for PTM patients and shared decision-making as a novel method for individualizing care.
全球范围内甲状腺癌的发病率正在上升。三分之一的新发甲状腺癌病例为甲状腺微小乳头状癌（PTM），肿瘤直径在 1 厘米或以下。这些肿瘤大多为惰性，预后极好。虽然甲状腺手术是治疗 PTM 患者最常见的选择，但新的治疗方法要求根据患者的偏好、情况和生物学特征，进行个体化的治疗决策。本文介绍了 PTM 患者的治疗选择和共享决策，作为一种个体化治疗的新方法。
Zotero 插件